Germline VHL gene mutations in Hungarian families with von Hippel-Lindau disease and patients with apparently sporadic unilateral pheochromocytomas

European Journal of Endocrinology

Volumn 161, Issue 3, 2009, Pages 495-502

  Gergics, Peter ^a   Patocs, Attila ^a   Toth, Miklos ^a   Igaz, Peter ^a   Szucs, Nikolette ^a   Liko, Istvan ^b   Fazakas, Ferenc ^c   Szabo, Istvan ^d   Kovacs, Balazs ^d   Glaz, Edit ^a   Racz, Karoly ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d SZENT ISTVÁN UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; FAMILY; FEMALE; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; VON HIPPEL LINDAU DISEASE; ADRENAL TUMOR; GENETIC SCREENING; GENETICS; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE;

ADRENAL GLAND NEOPLASMS; ADULT; CHILD; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; HUNGARY; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; VON HIPPEL-LINDAU DISEASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN; YOUNG ADULT;

EID: 70349251877     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-09-0399     Document Type: Article

References (54)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, ModiW, Geil L, Schmidt L, Zhou F, Li H, Chen F, Glenn G, Choyke P, Walther MM, Weng Y, Dean M, Glavac D, Richards FM, Crossey PA, Ferguson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B & Lerman MI. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993 260 1317-1320. (Pubitemid 23231974)
2. McGrath FP, Gibney RG, Morris DC, Owen DA & Erb SR. Case report: multiple hepatic and pulmonary haemangioblastomas - a new manifestation of von Hippel-Lindau disease. Clinical Radiology 1992 45 37-39.
3. Rojiani AM, Owen DA, Berry K, Woodhurst B, Anderson FH, Scudamore CH & Erb S. Hepatic hemangioblastoma. An unusual presentation in a patient with von Hippel-Lindau disease. American Journal of Surgical Pathology 1991 15 81-86.
4. Burns C, Levine PH, Reichman H & Stock JL. Adrenal hemangioblastoma in von Hippel-Lindau disease as a cause of secondary erythrocytosis. American Journal of the Medical Sciences 1987 293 119-121. (Pubitemid 17101972)
5. Friedrich CA. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Human Molecular Genetics 2001 10 763-767. (Pubitemid 32331586)
6. Maher ER, Webster AR, Richards FM, Green JS, Crossey PA, Payne SJ & Moore AT. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. Journal of Medical Genetics 1996 33 328-332. (Pubitemid 26102462)
7. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM & Oldfield EH. von Hippel-Lindau disease. Lancet 2003 361 2059-2067.
8. Gao J, Naglich JG, Laidlaw J, Whaley JM, Seizinger BR & Kley N. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Research 1995 55 743-747.
9. Blankenship C, Naglich JG, Whaley JM, Seizinger B & Kley N. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999 18 1529-1535. (Pubitemid 29108052)
10. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW & Kaelin WG Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Molecular and Cellular Biology 1998 18 732-741. (Pubitemid 28063406)
11. Schoenfeld A, Davidowitz EJ & Burk RD. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. PNAS 1998 95 8817-8822. (Pubitemid 28350572)
12. Stebbins CE, Kaelin WG Jr & Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999 284 455-461. (Pubitemid 29289612)
13. Beroud C, Joly D, Gallou C, Staroz F, Orfanelli MT & Junien C. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Research 1998 26 256-258. (Pubitemid 28295283)
14. van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW & Koper JW. Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. International Journal of Cancer 1998 77 337-340. (Pubitemid 28299866)
15. Li C, Weber G, Ekman P, Lagercrantz J, Norlen BJ, Akerstrom G, Nordenskjold M & Bergerheim US. Germline mutations detected in the von Hippel-Lindau disease tumor suppressor gene by Southern blot and direct genomic DNA sequencing. Human Mutation 1998 10 S31-S33. (Pubitemid 128670252)
16. Olschwang S, Richard S, Boisson C, Giraud S, Laurent-Puig P, Resche F & Thomas G. Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. Human Mutation 1998 12 424-430. (Pubitemid 28512619)
17. Dollfus H, Massin P, Taupin P, Nemeth C, Amara S, Giraud S, Beroud C, Dureau P, Gaudric A, Landais P & Richard S. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Investigative Ophthalmology & Visual Science 2002 43 3067-3074. (Pubitemid 34977061)
18. Neumann HP & Wiestler OD. Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus. Lancet 1991 337 1052-1054.
19. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, FrankeG, Schipper J, Klisch J, Altehoefer C, Zerres K, Januszewicz A, Eng C, Smith WM, Munk R, Manz T, Glaesker S, Apel TW, Treier M, Reineke M, Walz MK, Hoang-Vu C, Brauckhoff M, Klein-Franke A, Klose P, Schmidt H, Maier-Woelfle M, Peczkowska M, Szmigielski C & Eng C. Germ-line mutations in nonsyndromic pheochromocytoma. New England Journal of Medicine 2002 346 1459-1466.
20. Crossey PA, Eng C, Ginalska-Malinowska M, Lennard TW, Wheeler DC, Ponder BA & Maher ER. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. Journal of Medical Genetics 1995 32 885-886.
21. Woodward ER, Eng C, McMahon R, Voutilainen R, Affara NA, Ponder BA & Maher ER. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL. Human Molecular Genetics 1997 6 1051-1056. (Pubitemid 27308389)
22. Bar M, Friedman E, Jakobovitz O, Leibowitz G, Lerer I, Abeliovich D & Gross DJ. Sporadic phaeochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes. Clinical Endocrinology 1997 47 707-712. (Pubitemid 28046559)
23. Patocs A, Gergics P, Balogh K, Toth M, Fazakas F, Liko I & Racz K. Ser80Ile mutation and a concurrent Pro25Leu variant of the VHL gene in an extended Hungarian von Hippel-Lindau family. BMC Medical Genetics 2008 9 29. (Pubitemid 351622426)
24. Pastore YD, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L & Prchal JT. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2003 101 1591-1595. (Pubitemid 36182539)
25. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell AJ, Robinson PA, Inglehearn CF, Isaacs JD & Markham AF. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnology 2003 3 18. (Pubitemid 38846458)
26. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, Maher ER, Stanley AJ, Harnden P, Joyce A, Knowles M & Selby PJ. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Research 2006 66 2000-2011.
27. Shields CL, Shields JA, Barrett J & De Potter P. Vasoproliferative tumors of the ocular fundus. Classification and clinical manifestations in 103 patients. Archives of Ophthalmology 1995 113 615-623.
28. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara NA, Ferguson-Smith MA & Maher ER. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Human Molecular Genetics 1994 3 1303-1308. (Pubitemid 124000498)
29. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M, Gnarra JR, Orcutt ML, Duh FM, Glenn G, Green JD, Hsia YE, Lamiell JF, Li H, Wei MH, Schmidt L, Tory K, Kuzmin I, Stackhouse T, Latif F, Linehan WM, Lerman M & Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Human Mutation 1995 5 66-75. (Pubitemid 28512618)
30. Hes F, Zewald R, Peeters T, Sijmons R, Links T, Verheij J, Matthijs G, Leguis E, Mortier G, van der Torren K, Rosman M, Lips C, Pearson P & van der Luijt R. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Human Genetics 2000 106 425-431. (Pubitemid 30237510)
31. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, Crossey PA, Webster AR, Affara NA, Ferguson-Smith MA, Brauch H, Glavac D, Neumann HP, Tisherman S, Mulvihill JJ, Gross DJ, Shuin T, Whaley J, Seizinger B, Kley N, Olschwang S, Boisson C, Richard S, Lips CH & Lerman M. Germline mutations in the von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation 1996 8 348-357. (Pubitemid 26412151)
32. Casarin A, Martella M, Polli R, Leonardi E, Anesi L & Murgia A. Molecular characterization of large deletions in the von Hippel-Lindau (VHL) gene by quantitative real-time PCR: the hypothesis of an alu-mediated mechanism underlying VHL gene rearrangements. Molecular Diagnosis and Therapy 2006 10 243-249. (Pubitemid 44223238)
33. Cybulski C, Krzystolik K, Murgia A, Gorski B, Debniak T, Jakubowska A, Martella M, Kurzawski G, Prost M, Kojder I, Limon J, Nowacki P, Sagan L, Bialas B, Kaluza J, Zdunek M, Omulecka A, Jaskolski D, Kostyk E, Koraszewska- Matuszewska B, HausO, Janiszewska H, Pecold K, Starzycka M, Slomski R, CwirkoM, Sikorski A, Gliniewicz B, Cyrylowski L, Fiszer-Maliszewska L, Gronwald J, Toloczko-Grabarek A, Zajaczek S & Lubinski J. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene. Journal of Medical Genetics 2002 39 E38.
34. Rothberg PG, Bradley JF, Baker DW & Huelsman KM. Is the P25L a "real" VHL mutation? Molecular Diagnosis & Therapy 2001 6 49-54.
35. Pettman RK, Crowley A, Riddell C & Ludman MD. VHL P25L is not a pathogenic von Hippel-Lindau mutation: a family study. Molecular Diagnosis and Therapy 2006 10 239-242. (Pubitemid 44223237)
36. Hergovich A, Lisztwan J, Thoma CR, Wirbelauer C, Barry RE & KrekW. Priming-dependent phosphorylation and regulation of the tumor suppressor pVHL by glycogen synthase kinase 3. Molecular and Cellular Biology 2006 26 5784-5796.
37. Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE & Ohh M. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. Journal of Biological Chemistry 2005 280 22205-22211. (Pubitemid 40827877)
38. Ang SO, Chen H, Gordeuk VR, Sergueeva AI, Polyakova LA, Miasnikova GY, Kralovics R, Stockton DW & Prchal JT. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells, Molecules & Diseases 2002 28 57-62. (Pubitemid 34408988)
39. Wiesener MS, Seyfarth M, Warnecke C, Jurgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U & Eckardt KU. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002 99 3562-3565. (Pubitemid 34534523)
40. Pastore Y, Jedlickova K, Guan Y, Liu E, Fahner J, Hasle H, Prchal JF & Prchal JT. Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. American Journal of Human Genetics 2003 73 412-419. (Pubitemid 36921004)
41. Cario H, Schwarz K, Jorch N, Kyank U, Petrides PE, Schneider DT, Uhle R, Debatin KM & Kohne E. Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005 90 19-24. (Pubitemid 40193749)
42. Bento MC, Chang KT, Guan Y, Liu E, Caldas G, Gatti RA & Prchal JT. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica 2005 90 128-129. (Pubitemid 40193764)
43. Randi ML, Murgia A, Putti MC, Martella M, Casarin A, Opocher G & Fabris F. Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin. Haematologica 2005 90 689-691. (Pubitemid 40780890)
44. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clinical Cancer Research 2004 10 6290S-6295S.
45. Perrotta S, Nobili B, Ferraro M, Migliaccio C, Borriello A, Cucciolla V, Martinelli V, Rossi F, Punzo F, Cirillo P, Parisi G, Zappia V, Rotoli B & Ragione FD. Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster. Blood 2006 107 514-519. (Pubitemid 43076373)
46. Crawford ED, Henning DC &Wendel RG. Renal cell carcinoma in a horseshoe kidney associated with von Hippel-Lindau disease. Journal of Urology 1979 121 677-678. (Pubitemid 9180277)
47. Richards FM, Schofield PN, Fleming S & Maher ER. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Human Molecular Genetics 1996 5 639-644. (Pubitemid 26141278)
48. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM & Pacak K. New insights into the genetics of familial chromaffin cell tumors. Annals of the New York Academy of Sciences 2002 970 11-28. (Pubitemid 35286080)
49. Maher ER & Eng C. The pressure rises: update on the genetics of phaeochromocytoma. Human Molecular Genetics 2002 11 2347-2354. (Pubitemid 35174697)
50. Lenders JW, Eisenhofer G, Mannelli M & Pacak K. Phaeochromocytoma. Lancet 2005 366 665-675.
51. Korpershoek E, Van Nederveen FH, Dannenberg H, Petri BJ, Komminoth P, Perren A, Lenders JW, Verhofstad AA, De Herder WW, De Krijger RR & Dinjens WN. Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience. Annals of the New York Academy of Sciences 2006 1073 138-148. (Pubitemid 44912006)
52. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez- Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM & Tischler AS. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nature Clinical Practice. Endocrinology & Metabolism 2007 3 92-102. (Pubitemid 46146962)
53. Neumann HP, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B & Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. New England Journal of Medicine 1993 329 1531-1538. (Pubitemid 23332438)
54. Miller F, Kentsis A, Osman R & Pan ZQ. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia- inducible transcription factor-1alpha complex. Journal of Biological Chemistry 2005 280 7985-7996. (Pubitemid 40349696)